VICTORIA, BC, Sept. 9, 2020 /PRNewswire/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Firm” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a pacesetter in full-service, therapeutic antibody discovery and improvement, at this time introduced that it is going to be presenting on the H.C. Wainwright Annual World Funding Convention being held nearly on September 14-16, 2020.
Jennifer Bathtub, CEO of ImmunoPrecise, will present an summary of the Firm’s enterprise throughout the reside presentation and will likely be obtainable to take part in one-on-one conferences with traders who’re registered to attend the convention.
In case you are an institutional investor, and want to attend the Firm’s presentation, please click on on the next hyperlink (www.hcwevents.com) to register for the convention. As soon as your registration is confirmed, you may be prompted to log into the convention web site to request a one-on-one assembly with the Firm.
Occasion: H.C. Wainwright 22nd Annual World Funding Convention (Digital Convention)
Date: September 14-16, 2020
Presentation Day & Time: September 15, 12:30 PM (EDT)
H.C. Wainwright is a full-service funding financial institution devoted to offering company finance, strategic advisory and associated providers to private and non-private firms throughout a number of sectors and areas. H.C. Wainwright & Co. additionally supplies analysis and gross sales and buying and selling providers to institutional traders. Based on Sagient Analysis Programs, H.C. Wainwright’s crew is ranked because the #1 Placement Agent when it comes to mixture CMPO (confidentially marketed public providing), RD (registered direct providing) and PIPE (non-public funding in public fairness) executed cumulatively since 1998.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a worldwide know-how platform firm with end-to-end options empowering firms to find and develop therapies towards any illness. The Firm’s expertise and cutting-edge applied sciences allow unparalleled assist of its companions of their quest to carry revolutionary remedies to the clinic. ImmunoPrecise’s full-service capabilities dramatically cut back the time required for, and the inherent danger related to, typical multi-vendor product improvement. For additional data, go to www.immunoprecise.com or contact [email protected].
Ahead Wanting Data
This information launch accommodates statements that, to the extent they don’t seem to be recitations of historic reality, might represent “forward-looking statements” inside the which means of relevant Canadian securities legal guidelines. The Firm makes use of phrases akin to “might”, “would”, “may”, “will”, “seemingly”, “anticipate”, “imagine”, “intend”, “ought to” and related expressions to establish forward-looking statements. Any such forward-looking statements are primarily based on assumptions and analyses made by ImmunoPrecise in mild of its expertise and its notion of historic developments, present situations and anticipated future developments. Nevertheless, whether or not precise outcomes and developments will conform to ImmunoPrecise’s expectations and predictions is topic to any variety of dangers, assumptions and uncertainties. Many elements may trigger ImmunoPrecise’s precise outcomes to vary materially from these expressed or implied by the forward-looking statements contained on this information launch. Such elements embody, amongst different issues, precise revenues and earnings for IPA being decrease than anticipated, and people dangers and uncertainties described in ImmunoPrecise’s annual administration dialogue and evaluation for the earlier quarter and audited fiscal 12 months ended April 30, 2020, which could be accessed at www.sedar.com. The “forward-looking statements” contained herein converse solely as of the date of this press launch and, until required by relevant legislation, ImmunoPrecise undertakes no obligation to publicly replace or revise such data, whether or not on account of new data, future occasions or in any other case.
Neither the TSX Enterprise Change nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Change) accepts duty for the adequacy or accuracy of this launch.
SOURCE ImmunoPrecise Antibodies Ltd.